|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.070 USD | -3.27% |
|
-5.48% | -74.22% |
| 05-07 | Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-21 | Lipocine Inc Spyros Papapetropoulos resigns as board member effective April 16, 2026 | RE |
Evolution of the Average Target: Lipocine Inc.
Evolution of the Target Price: Lipocine Inc.
Changes in Analyst Recommendations: Lipocine Inc.
42.4eBsKpJUZLkR7Jk3uKETh6F5joGoQY4ygJwW7abEn-w.rLQYGdsjPsl3nexF9uhBv_sr6uPBF8pV6MRy2J6M3oi3qDhw1AMT41Kl-g~01b2fe56ab700446eadfecc94fc52bf8
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | +180.37% | |||
| +17.07% | |||||
| +22.32% | |||||
| +31.93% | |||||
| +88.4% | |||||
| +22.04% | |||||
| +25.37% | |||||
| +11.53% | |||||
| -3.74% | |||||
| -7.86% | |||||
| Average | +38.74% | |||||
| Weighted average by Cap. | +24.48% |
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.070USD
Average target price
6.000USD
Spread / Average Target
+189.86%
High Price Target
6.000USD
Spread / Highest target
+189.86%
Low Price Target
6.000USD
Spread / Lowest Target
+189.86%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| HC Wainwright | |
| Alliance Global Partners | |
| Cantor Fitzgerald | |
| Ladenburg Thalmann |
SellBuy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.070USD
Average target price
6.000USD
Spread / Average Target
+189.86%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- LPCN Stock
- Consensus Lipocine Inc.
Select your edition
All financial news and data tailored to specific country editions
